RCUS

Arcus Biosciences, Inc.

21.46

USD

RCUS Earnings Reports

Positive Surprise Ratio

RCUS beat 18 of 32 last estimates.

56%

Next Report

Date of Next Report

May 04, 2026

Estimate for Q1 26 (Revenue/ EPS)

$27.50M

-$0.96

Implied change from Q4 25 (Revenue/ EPS)

-16.68%

+7.87%

Implied change from Q1 25 (Revenue/ EPS)

-1.80%

-15.04%

Arcus Biosciences, Inc. earnings per share and revenue

On Feb 25, 2026, RCUS reported earnings of -0.89 USD per share (EPS) for Q4 25, beating the estimate of -1.04 USD, resulting in a 14.97% surprise. Revenue reached 33.00 million, compared to an expected 36.43 million, with a -9.40% difference. The market reacted with a -3.60% price change (close before vs. close after earnings).

Looking ahead to Q1 26, 7 analysts forecast an EPS of -0.96 USD, with revenue projected to reach 27.50 million USD, implying an increase of 7.87% EPS, and decrease of -16.68% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Celcuity Inc. Common Stock

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$1.06

Actual

-$0.97

Surprise

+8.72%

Precigen, Inc. Common Stock

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$0.08

Actual

-$0.01

Surprise

+88.24%

Absci Corporation Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.19

Actual

-$0.23

Surprise

-16.04%

Candel Therapeutics, Inc. Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.25

Actual

-$0.54

Surprise

-115.31%

LENZ Therapeutics, Inc. Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.99

Actual

-$1.15

Surprise

-17.10%

Fennec Pharmaceuticals Inc. Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

$0.03

Actual

-$0.11

Surprise

-408.12%

Equillium, Inc. Common Stock

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$0.06

Actual

-$0.04

Surprise

+35.28%

MaxCyte, Inc. Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.08

Actual

-$0.06

Surprise

+26.47%

Dyadic International, Inc.

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$0.04

Actual

-$0.06

Surprise

-30.72%

TELA Bio, Inc. Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.18

Actual

-$0.16

Surprise

+14.12%

FAQ

What were Arcus Biosciences, Inc.'s earnings and revenue for the latest quarter Q4 2025?

For Q4 2025, Arcus Biosciences, Inc. reported EPS of -$0.89, beating estimates by 14.97%, and revenue of $33.00M, -9.4% below expectations.

How did the market react to Arcus Biosciences, Inc.'s Q4 2025 earnings?

The stock price moved down -3.6%, changed from $20.27 before the earnings release to $19.54 the day after.

When is Arcus Biosciences, Inc. expected to report next?

The next earning report is scheduled for May 04, 2026.

What are the forecasts for Arcus Biosciences, Inc.'s next earnings report?

Based on 7 analysts, Arcus Biosciences, Inc. is expected to report EPS of -$0.96 and revenue of $27.50M for Q1 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.